CDK5 and obesity disorder: As Pparγ upstream factors such as CDK5 are considered as new molecular targets for insulin resistance and other metabolic diseases, mechanism studies of these compounds may provide new molecular targets for obesity and obesity-related metabolic diseases [31,32].